Feeder Cattle (FC)

La vendita allo scoperto per Franklin Covey dà agli investitori un'idea del grado in cui gli investitori stanno scommettendo sul declino delle azioni di Franklin Covey. I dati relativi alle vendite allo scoperto vengono aggiornati ogni due settimane.

Franklin Covey (NYSE:FC) Azioni, Report sulle vendite allo scoperto

Franklin Covey

Franklin Covey Co is a global company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education practice, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the United States and other international countries.

Franklin Covey Co

HSBC BANK 28/10/24 WNT

First Trust China AlphaDEX Fund

FIRM CAP APART RL EST INVST UNT

Firm Capital Apartment REIT

First Trust California Municipal High income ETF

First Capital Inc

STELLANTIS ORD

FINECOBANK BANCA FINE SPA by Finecobank Banca Fineco SPA

FinecoBank SpA

First Community Bankshares, Inc. - Common Stock

First Community Bankshares Inc

Fast Casual Concepts Inc

FAST CASUAL CONCEPTS NEW by FAST CASUAL CONCEPTS INC.

SPECTRAL CAPITAL CORP by Spectral Capital Corp.

Spectral Capital Corp

First Community Corporation - Common Stock

First Community Corp

FIRST COMMUNITY CORP (TN) by First Community Corp. (TN)

First Community Corp Tn

FIRST CMNTY CRP PR B (TN) by First Community Corp. (TN)

FIRST CMNTY CRP PR A (TN) by First Community Corp. (TN)

FRANCE BED HLDGS by France Bed Holdings Co., Ltd.

France Bed Holdings Co Ltd

First Trust Income Opportunities ETF

FuelCell Energy Inc

FUELCELL ENERGY INC PFD B by FuelCell Energy, Inc.

First Commonwealth Financial Corporation Common Stock

First Commonwealth Financial Corp

FirstCash Holdings Inc

First Trust Exchange-Traded Fund First Trust S&P 500 Diversified Free Cash Flow ETF

First Trust Natural Gas ETF

FIDELITY GLOBAL CR PLS BD SRS L ETF

FIRST COLOMBIA GLD CORP by First Colombia Gold Corp.

First Colombia Gold Corp

FCG INC by FCG, Inc.

FIDELITY GLOB SMALL CAP OPPO UNT ETF

FLORIDA CANYON GOLD INC by FLORIDA CANYON GOLD INC

FORECASTAGILITY CORP by Forecastagility Corporation

Forecastagility Corp

Fitness Champs Holdings Ltd

Georg Fischer AG

FIRST CHOICE HLTHCRE INC by First Choice Healthcare Solutions, Inc.

First Choice Healthcare Solutions Inc

FCCC Inc

FIDELITY GLOBAL INV GRD BD SRS L ETF

FIDELITY INTERNATIONAL HIGH QTY ETF

Fractal - United States Dollar

Fidelity Cloud Computing ETF

FIDELITY UCITS ICAV ETF

FULL CIRCLE LITHIUM CORP by Full Circle Lithium Corp.

Full Circle Lithium Corp

FIRSTWAVE CLOUD TECH by Firstwave Cloud Technology Ltd.

FirstWave Cloud Technology Ltd

FIRM CAP MTG INVST CORP by Firm Capital Mortgage Investment Corp

Firm Capital Mortgage Investment Corp

FIDELITY US MOMENTUM ETF

FTI Consulting Inc

First Citizens BancShares, Inc. - Class A Common Stock

First Citizens BancShares Inc

FIRST CTZNS BANCSHS B by First Citizens BancShares, Inc.

First Citizens BancShares, Inc. - 5.625% Non-Cumulative Perpetual Preferred Stock, Series C

First Citizens BancShares, Inc. - Depositary Shares Each Representing a 1/40th Interest in a Share of 5.375% Non-Cumulative Perpetual Preferred Stock, Series A

Four Corners Inc. Com

abrdn Global Income Fund, Inc. Common Stock

abrdn Global Income Fund Inc

1ST COLONIAL BANCORP INC by 1st Colonial Bancorp, Inc.

1st Colonial Bancorp Inc

COMPAGNIE DE L ODET by COMPAGNIE DE L ODET

Compagnie de l`Odet

Fidelity MSCI Communication Services Index ETF

SpaceFalcon

Fidelity Corporate Bond ETF

Barrington Research analyst Alexander Paris maintains Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and maintains $45 price target.

News

Price Target

Analyst Ratings

Barrington Research Maintains Outperform on Franklin Covey, Maintains $45 Price Target

Roth MKM analyst Jeff Martin reiterates Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Buy and maintains $50 price target.

Reiteration

Roth MKM Reiterates Buy on Franklin Covey, Maintains $50 Price Target

Guidance

Franklin Covey Continues To Expect FY24 Adj. EBITDA At Low End Of $54.5M-$58M Range

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.39 by 10.26 percent. The company reported quarterly sales of $73.373 million which beat the analyst consensus estimate of $72.118 million by 1.74 percent. This is a 2.70 percent increase over sales of $71.441 million the same period last year.

Earnings

Earnings Beats

Franklin Covey Q3 2024 GAAP EPS $0.43 Beats $0.39 Estimate, Sales $73.373M Beat $72.118M Estimate

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $55.0, a high estimate of $95.00, and a low estimate of $45.00. Observing a downward trend, the current average is 5.17% lower than the prior average price target of $58.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1718726443_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Franklin Covey. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Franklin Covey. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Franklin Covey compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Franklin Covey's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
To gain a panoramic view of Franklin Covey's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Franklin Covey analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Discovering Franklin Covey: A Closer Look</h2>
Franklin Covey Co is a global company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education practice, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the United States and other international countries.
<h3>Franklin Covey's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Franklin Covey's revenue growth over a period of 3 months has faced challenges. As of 29 February, 2024, the company experienced a revenue decline of approximately -0.68%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Industrials sector.
Net Margin: Franklin Covey's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of 1.42%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Franklin Covey's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of 1.24%, the company may face hurdles in achieving optimal financial returns.
Return on Assets (ROA): Franklin Covey's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.4%, the company may face hurdles in achieving optimal financial performance.
Debt Management: Franklin Covey's debt-to-equity ratio is below the industry average at 0.16, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>How Are Analyst Ratings Determined?</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Cracking The Code: Understanding Analyst Reviews For Franklin Covey

During the last three months, 5 analysts shared their evaluations of Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $57.0, a high estimate of $95.00, and a low estimate of $45.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 6.94%. 
<img src="https://www.benzinga.com/files/images/story/2024/1716915689_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
The perception of Franklin Covey by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Franklin Covey. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Franklin Covey compared to the broader market.</li>
<li>Price Targets: Gaining insights, analysts provide estimates for the future value of Franklin Covey's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Franklin Covey's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/FC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Franklin Covey analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>About Franklin Covey</h2>
Franklin Covey Co is a global company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education practice, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the United States and other international countries.
<h3>Unraveling the Financial Story of Franklin Covey</h3>
Market Capitalization Analysis: Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Franklin Covey's financials over 3 months reveals challenges. As of 29 February, 2024, the company experienced a decline of approximately -0.68% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Franklin Covey's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of 1.42%, the company may encounter challenges in effective cost control.
Return on Equity (ROE): Franklin Covey's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 1.24%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Franklin Covey's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of 0.4%, the company may face hurdles in achieving optimal financial performance.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.16.
<h2>Analyst Ratings: Simplified</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Franklin Covey: What You Need To Know

Buybacks

Franklin Covey Board Approves $50M Purchase Plan

In the latest quarter, 4 analysts provided ratings for Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>), showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $62.5, with a high estimate of $95.00 and a low estimate of $45.00. This current average represents a 19.35% decrease from the previous average price target of $77.50. 
<img src="https://www.benzinga.com/files/images/story/2024/1711645261_0.png" alt="price target chart" />
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Franklin Covey. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nehal Chokshi</td>
<td>Northland Capital Markets</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$95.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$45.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Alexander Paris</td>
<td>Barrington Research</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Franklin Covey. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Franklin Covey compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Franklin Covey's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Franklin Covey's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/FC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Franklin Covey analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.
<h2>Delving into Franklin Covey's Background</h2>
Franklin Covey Co is a global company focused on organizational performance improvement. It focuses on providing time management and effectiveness training for individuals and corporations via online training as well as in-person workshops and events. The company provides training and consulting services in the areas of leadership, execution, productivity, trust, sales performance, customer loyalty, and educational improvement. It operates in the business segments of Direct Offices, Education practice, and International Licensees. The company derives revenue from providing training and consulting services, and through the selling of books, audio media, and other related products. It has a business presence in the United States and other international countries.
<h3>Franklin Covey's Financial Performance</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Negative Revenue Trend: Examining Franklin Covey's financials over 3 months reveals challenges. As of 30 November, 2023, the company experienced a decline of approximately -1.4% in revenue growth, reflecting a decrease in top-line earnings. When compared to others in the Industrials sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Franklin Covey's net margin excels beyond industry benchmarks, reaching 7.09%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Franklin Covey's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 6.5% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): Franklin Covey's ROA excels beyond industry benchmarks, reaching 2.09%. This signifies efficient management of assets and strong financial health.
Debt Management: Franklin Covey's debt-to-equity ratio is below the industry average at 0.19, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings For Franklin Covey

Northland Capital Markets analyst Nehal Chokshi maintains Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and lowers the price target from $100 to $95.

Northland Capital Markets Maintains Outperform on Franklin Covey, Lowers Price Target to $95

Barrington Research analyst Alexander Paris maintains Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and lowers the price target from $55 to $45.

Barrington Research Maintains Outperform on Franklin Covey, Lowers Price Target to $45

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported its Q2 earnings results on Wednesday, March 27, 2024 at 04:05 PM.
Here's what investors need to know about the announcement.
<h3>Earnings</h3>
Franklin Covey beat estimated earnings by 20.0%, reporting an EPS of $0.06 versus an estimate of $0.05.
Revenue was down $420 thousand from the same period last year.
<h3>Past Earnings Performance</h3>
Last quarter the company beat on EPS by $0.13 which was followed by a 3.0% increase in the share price the next day.
Here's a look at Franklin Covey's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.48</td>
<td>0.22</td>
<td>0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.49</td>
<td>0.32</td>
<td>0.12</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>65.88M</td>
<td>81.60M</td>
<td>69.62M</td>
<td>62.40M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>68.40M</td>
<td>77.95M</td>
<td>71.44M</td>
<td>61.76M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Franklin Covey <a href="https://www.benzinga.com/quote/FC/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Recap: Franklin Covey Q2 Earnings

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) reported quarterly earnings of $0.06 per share which beat the analyst consensus estimate of $0.05 by 20 percent. This is a 50 percent decrease over earnings of $0.12 per share from the same period last year. The company reported quarterly sales of $61.34 million which missed the analyst consensus estimate of $62.02 million by 1.10 percent. This is a 0.68 percent decrease over sales of $61.76 million the same period last year.

Franklin Covey Q2 EPS $0.06 Beats $0.05 Estimate, Sales $61.34M Miss $62.02M Estimate

<h3>Companies Reporting Before The Bell</h3>
&bull; Local Bounti (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LOCL#NYSE">LOCL</a>) is projected to report quarterly loss at $2.41 per share on revenue of $8.70 million.
&bull; REE Automotive (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REE#NASDAQ">REE</a>) is estimated to report quarterly loss at $2.38 per share on revenue of $1.35 million.
&bull; Precision BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DTIL#NASDAQ">DTIL</a>) is projected to report quarterly loss at $2.05 per share on revenue of $12.48 million.
&bull; Edap TMS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDAP#NASDAQ">EDAP</a>) is expected to report quarterly loss at $0.05 per share on revenue of $19.66 million.
&bull; Vanguard Extended Duration Treasury ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EDV#NYSE">EDV</a>) is expected to report earnings for its fourth quarter.
&bull; Cellectar Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLRB#NASDAQ">CLRB</a>) is likely to report earnings for its fourth quarter.
&bull; Gamida Cell (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMDA#NASDAQ">GMDA</a>) is projected to report quarterly loss at $0.15 per share on revenue of $1.06 million.
&bull; PDS Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PDSB#NASDAQ">PDSB</a>) is likely to report earnings for its fourth quarter.
&bull; Altimmune (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALT#NASDAQ">ALT</a>) is projected to report earnings for its fourth quarter.
&bull; Syros Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SYRS#NASDAQ">SYRS</a>) is estimated to report quarterly loss at $1.14 per share on revenue of $2.00 million.
&bull; Lands&#39; End (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LE#NASDAQ">LE</a>) is expected to report quarterly earnings at $0.21 per share on revenue of $502.71 million.
&bull; Cintas (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTAS#NASDAQ">CTAS</a>) is projected to report quarterly earnings at $3.58 per share on revenue of $2.39 billion.
&bull; GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) is projected to report earnings for its fourth quarter.
&bull; Sonida Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SNDA#NYSE">SNDA</a>) is projected to report earnings for its fourth quarter.
&bull; UniFirst (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNF#NYSE">UNF</a>) is projected to report quarterly earnings at $1.42 per share on revenue of $587.84 million.
<h3>Companies Reporting After The Bell</h3>
&bull; Creative Media (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCT#NASDAQ">CMCT</a>) is estimated to report quarterly loss at $0.48 per share on revenue of $30.20 million.
&bull; Draganfly (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DPRO#NASDAQ">DPRO</a>) is likely to report earnings for its fourth quarter.
&bull; VNET Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNET#NASDAQ">VNET</a>) is projected to report quarterly loss at $0.18 per share on revenue of $279.03 million.
&bull; RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) is estimated to report quarterly earnings at $1.67 per share on revenue of $777.48 million.
&bull; American Shared Hospital (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/AMS#AMEX">AMS</a>) is estimated to report quarterly earnings at $0.02 per share on revenue of $5.19 million.
&bull; Cosan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CSAN#NYSE">CSAN</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $7.45 billion.
&bull; Greenidge Generation Hldg (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GREE#NASDAQ">GREE</a>) is estimated to report quarterly earnings at $0.25 per share on revenue of $26.70 million.
&bull; Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $21.00 million.
&bull; Allied Gaming (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AGAE#NASDAQ">AGAE</a>) is projected to report earnings for its fourth quarter.
&bull; Jefferies Financial Gr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JEF#NYSE">JEF</a>) is likely to report quarterly earnings at $0.75 per share on revenue of $1.52 billion.
&bull; LogicMark (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGMK#NASDAQ">LGMK</a>) is expected to report quarterly loss at $1.73 per share on revenue of $2.28 million.
&bull; H.B. Fuller (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FUL#NYSE">FUL</a>) is projected to report quarterly earnings at $0.64 per share on revenue of $825.03 million.
&bull; Sprinklr (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CXM#NYSE">CXM</a>) is likely to report quarterly earnings at $0.09 per share on revenue of $188.73 million.
&bull; Dynagas LNG Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLNG#NYSE">DLNG</a>) is expected to report quarterly earnings at $0.30 per share on revenue of $38.21 million.
&bull; Durect (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRRX#NASDAQ">DRRX</a>) is estimated to report quarterly loss at $0.33 per share on revenue of $2.48 million.
&bull; Celcuity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CELC#NASDAQ">CELC</a>) is expected to report earnings for its fourth quarter.
&bull; BioCardia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCDA#NASDAQ">BCDA</a>) is estimated to report quarterly loss at $0.11 per share on revenue of $90 thousand.
&bull; Consolidated Water Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CWCO#NASDAQ">CWCO</a>) is likely to report quarterly earnings at $0.44 per share on revenue of $45.25 million.
&bull; Silver Spike Investment (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSIC#NASDAQ">SSIC</a>) is projected to report quarterly earnings at $0.27 per share on revenue of $3.37 million.
&bull; Urban-gro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UGRO#NASDAQ">UGRO</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $28.94 million.
&bull; PLBY Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLBY#NASDAQ">PLBY</a>) is estimated to report quarterly loss at $0.14 per share on revenue of $32.27 million.
&bull; Usio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/USIO#NASDAQ">USIO</a>) is projected to report quarterly earnings at $0.00 per share on revenue of $20.43 million.
&bull; Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is estimated to report quarterly earnings at $0.05 per share on revenue of $62.02 million.
&bull; Super League Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLE#NASDAQ">SLE</a>) is estimated to report quarterly loss at $1.20 per share on revenue of $9.30 million.
&bull; Spectral AI (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDAI#NASDAQ">MDAI</a>) is estimated to report quarterly loss at $0.40 per share on revenue of $4.60 million.
&bull; Strata Skin Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSKN#NASDAQ">SSKN</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $10.01 million.
&bull; Verint Systems (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRNT#NASDAQ">VRNT</a>) is estimated to report quarterly earnings at $0.97 per share on revenue of $263.12 million.
&bull; Eastside Distilling (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EAST#NASDAQ">EAST</a>) is projected to report quarterly loss at $0.90 per share on revenue of $3.68 million.
&bull; Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) is likely to report quarterly loss at $0.05 per share on revenue of $124.86 million.
&bull; Oncology Institute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TOI#NASDAQ">TOI</a>) is expected to report quarterly loss at $0.11 per share on revenue of $82.04 million.
&bull; Aqua Metals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AQMS#NASDAQ">AQMS</a>) is expected to report quarterly loss at $0.05 per share on revenue of $50 thousand.
&bull; Kingstone Companies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KINS#NASDAQ">KINS</a>) is estimated to report quarterly loss at $0.08 per share on revenue of $29.65 million.
&bull; MillerKnoll (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLKN#NASDAQ">MLKN</a>) is projected to report quarterly earnings at $0.44 per share on revenue of $909.50 million.
&bull; Rumble (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) is likely to report quarterly loss at $0.22 per share on revenue of $28.13 million.
This article was generated by Benzinga&#39;s automated content engine and reviewed by an editor.

AGAE

AQMS

BCDA

BRZE

CELC

CLRB

CMCT

CSAN

CTAS

CWCO

DLNG

DPRO

DRRX

DTIL

EAST

EDAP

GAIA

GLYC

GMDA

GREE

KINS

LGMK

LOCL

MDAI

MLKN

PDSB

PLBY

SNDA

SSIC

SSKN

SYRS

UGRO

USIO

VNET

VRNT

Earnings Scheduled For March 27, 2024

Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) is set to give its latest quarterly earnings report on Wednesday, 2024-03-27. Here's what investors need to know before the announcement.
Analysts estimate that Franklin Covey will report an earnings per share (EPS) of $0.05. 
Franklin Covey bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Historical Earnings Performance</h3>
Last quarter the company beat EPS by $0.13, which was followed by a 3.28% increase in the share price the next day.
Here's a look at Franklin Covey's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
<th>Q3 2023</th>
<th>Q2 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.23</td>
<td>0.48</td>
<td>0.22</td>
<td>0.13</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.36</td>
<td>0.49</td>
<td>0.32</td>
<td>0.12</td>
</tr>
<tr>
<td>Price Change %</td>
<td>3.0%</td>
<td>-9.0%</td>
<td>26.0%</td>
<td>-18.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2024/1711461711_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Franklin Covey were trading at $38.9 as of March 25. Over the last 52-week period, shares are down 12.14%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/FC/earnings">To track all earnings releases for Franklin Covey visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Franklin Covey

Barrington Research analyst Alexander Paris reiterates Franklin Covey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FC#NYSE">FC</a>) with a Outperform and maintains $55 price target.

Barrington Research Reiterates Outperform on Franklin Covey, Maintains $55 Price Target

U.S. stock futures were lower this morning, with the Dow Jones futures falling around 50 points on Friday.
Shares of Franklin Covey Co. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/fc#NYSE">FC</a>) fell sharply in pre-market trading after the company reported <a href="https://www.benzinga.com/news/earnings/24/01/36502545/franklin-covey-stock-rises-after-hours-on-q1-earnings-win-before-turning-lower">results for its first quarter.</a>
The company reported quarterly earnings of 36 cents, exceeding estimates of 23 cents per share. Revenue of $68.40 million clocked in above the analyst consensus estimate of $65.88 million.
Franklin Covey affirmed its outlook that adjusted EBITDA will grow to between $54.5 million and $58 million in constant currency in the full year 2024, versus $48.1 million achieved in the same period in 2023.
Franklin Covey shares fell 4.1% to $37.75 in pre-market trading.
Here are some big stocks recording losses in today&rsquo;s pre-market trading session.
<ul>
<li>Applied Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/aplt#NASDAQ">APLT</a>) shares declined 30.1% to $2.65 in pre-market trading after reporting topline results from ARISE-HF Phase 3 study of AT-001 in diabetic cardiomyopathy.</li>
<li>Theravance Biopharma, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/tbph#NASDAQ">TBPH</a>) shares fell 18.4% to $9.40 in pre-market trading after the company announced results from Phase 4 YUPELRI PIFR-2 study. The company said study did not show a statistically significant difference between yupelri and spiriva handihaler on primary endpoint.</li>
<li>Voyager Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/vygr#NASDAQ">VYGR</a>) shares tumbled 16.6% to $9.04 in pre-market trading. Voyager Therapeutics priced its public offering of 7,777,778 common shares at $9 per share.</li>
<li>Medical Properties Trust, Inc. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/mpw#NYSE">MPW</a>) shares dipped 14.2% to $4.29 in pre-market trading after the company issued an update on Steward Health Care. Keybanc analyst Austin Wurschmidt downgraded Medical Properties Trust from Overweight to Sector Weight.</li>
<li>Catalyst Pharmaceuticals, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/cprx#NASDAQ">CPRX</a>) shares fell 12.2% to $15.03 in pre-market trading after announcing a proposed public offering of common stock.</li>
<li>Allogene Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/allo#NASDAQ">ALLO</a>) shares declined 12.1% to $2.98 in pre-market trading. Allogene Therapeutics and Foresight Diagnostics disclosed a partnership to develop MRD-based in-vitro diagnostic for use in ALPHA3, the first pivotal trial for frontline consolidation in large B-cell lymphoma.</li>
<li>Dyne Therapeutics, Inc. (NASDAQ: <a class="ticker" href="https://www.benzinga.com/stock/dyn#NASDAQ">DYN</a>) shares fell 4.6% to $18.50 in pre-market trading. Dyne Therapeutics priced its $300 million public offering of 17.15 million common stock at $17.50 per share.</li>
<li>Corporaci&oacute;n Am&eacute;rica Airports S.A. (NYSE: <a class="ticker" href="https://www.benzinga.com/stock/caap#NYSE">CAAP</a>) shares declined 4.4% to $15.00 in pre-market trading.</li>
</ul>
&nbsp;
Now Read This: <a href="https://www.benzinga.com/news/earnings/24/01/36484759/fear-greed-index-moves-to-greed-zone-nasdaq-tumbles-for-4th-consecutive-day"> Fear &amp; Greed Index Moves To &#39;Greed&#39; Zone; Nasdaq Tumbles For 4th Consecutive Day </a>
Don&rsquo;t forget to check out our <a href="https://www.benzinga.com/premarket/"> premarket coverage here </a>

Penny Stocks

Small Cap

Pre-Market Outlook

Markets

Movers

Trading Ideas

ALLO

APLT

CAAP

CPRX

TBPH

VYGR

Franklin Covey Shares Fall After Q1 Results, Joins Theravance Biopharma, Voyager Therapeutics And Other Big Stocks Moving Lower In Friday's Pre-Market Session

Franklin Covey GAAP EPS of $0.43 beats by $0.04, revenue of $73.37M beats by $1.23M

The latest update is out from Franklin Covey Company (FC). The Company invites shareholders and the financial community to a live discussion on Jun...

Franklin Covey Discusses Q3 Fiscal 2024 Results Live

Franklin Covey Co. 2024 Q3 - Results - Earnings Call Presentation

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Franklin Covey (NYSE:<a href="https://investorplace.com/stock-quotes/fc-stock-quote/">FC</a>) just reported results for the third quarter of 2024.<ul><li>Franklin Covey reported earnings per share of 43 cents. This was above the analyst estimate for EPS of 39 cents.</li><li>The company reported revenue of $73.37 million.</li><li>This was 1.74% better than the analyst estimate for revenue of $72.12 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/06/fc-stock-earnings-franklin-covey-for-q3-of-2024/">FC Stock Earnings: Franklin Covey Beats EPS, Beats Revenue for Q3 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

FC Stock Earnings: Franklin Covey Beats EPS, Beats Revenue for Q3 2024

Franklin Covey Co. (FC) Q3 2024 Earnings Call Transcript

Roth MKM analyst Jeff Martin reiterated a Buy rating on Franklin Covey Company (FC – Research Report) today and set a price target of $50.00. The c...

Roth MKM Sticks to Their Buy Rating for Franklin Covey Company (FC)

Barrington analyst Alexander Paris has reiterated their bullish stance on FC stock, giving a Buy rating today. Alexander Paris has given his Buy ra...

Strong Q3 Performance and Positive Outlook Justify Outperform Rating for Franklin Covey Company

Franklin Covey: Expecting Growth To Accelerate In Upcoming Quarters

Warning: FC is at high risk of performing badly

Franklin Covey: Remains Attractively Priced After Q3

Press Releases

Franklin Covey to Report Second Quarter Fiscal 2024 Results

Franklin Covey Reports Second Quarter Fiscal 2024 Financial Results

Training Industry Selects FranklinCovey for Its 2024 Top 20 Leadership Training Companies List Again for the 14th Time

Franklin Covey Announces New Common Share Purchase Plan

Franklin Covey to Report Third Quarter Fiscal 2024 Financial Results

Franklin Covey Reports Strong Third Quarter Fiscal 2024 Financial Results

FranklinCovey Launches the FranklinCovey Mobile App

FranklinCovey Partners with World of Business Ideas to Have Renowned Thought Leaders and Bestselling Authors Present at 2024 World Business Forum Events

FranklinCovey Wins 2024 Training Magazine Network Choice Award for Outstanding Training Products and Solutions in Leadership Development, for the Fourth Time

Comments

Franklin Covey

Vendite allo scoperto

Franklin Covey (NYSE:FC) Azioni, Report sulle vendite allo scoperto

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO